Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
Lakewood-Amedex Biotherapeutics (LABT) announced that CEO Kelvin Cooper will participate in three industry conferences in October 2026, including two presentations.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lakewood-Amedex Biotherapeutics (LABT) announced that CEO Kelvin Cooper will participate in three industry conferences in October 2026, including two presentations.
He is scheduled to attend the Maxim Growth Summit in New York City on October 14 and attend and present at ThinkEquity there on October 15. He will present a poster on Nu-3 preclinical data at IDWeek in Washington, D.C., on October 22.
Details
Market Reaction – LABT
On Oct 1, the day this news came out, the latest delayed price for LABT is 2.70% below the previous close. Our momentum scanner has recorded 2 alerts for this stock so far that day. The latest delayed price is $0.93.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dr. Cooper is scheduled to attend the Maxim Growth Summit on October 14, 2026, in
Details are as follows:
|
Event: |
|
Maxim Growth Summit |
|
Date: |
|
October 13-14, 2026 |
|
Location: |
|
Hard Rock Hotel, |
|
|
|
|
|
Event: |
|
ThinkEquity Conference |
|
Date: |
|
October 15, 2026 |
|
Location: |
|
The Mandarin Oriental Hotel, |
|
Presentation: |
|
Nu-3 – A Novel, Broad Spectrum Antimicrobial Compound with High In- Vitro |
|
Presentation Time: |
|
3:30 pm |
|
|
|
|
|
Event: |
|
IDWeek |
|
Date: |
|
October 21-24, 2026 |
|
Location: |
|
Walter E. Washington Convention |
The conferences provide opportunities for Lakewood-Amedex to engage with members of the investment, biotechnology, and infectious disease communities and highlight the Company's ongoing development programs Bisphosphocin® antimicrobial technology.
About Lakewood-Amedex Biotherapeutics, Inc.
Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.
Contacts:
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com
Michelle Katsel
(201) 790-3390
mkatsel@tiberend.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-announces-participation-in-october-conferences-302895486.html
SOURCE Lakewood-Amedex Biotherapeutics Inc.